Forum Agenda
-
Medicine-Engineering Integration and Innovative Medical Devices
-
China’s Innovation Ecosystem and Models
-
Research Translation and Early-stage Project Incubation Meeting
-
Accelerating Innovation Through External Collaboration Meeting
-
Leveraging China's Innovation to Accelerate Global Drug R&D Meeting
-
USTC Original Innovation Power: Alumni Enterprise Innovation Matrix Meeting
-
Clinical Translation of Medical Research Achievements Meeting
-
Cross-Border Cooperation and China’s New Drug Global Expansion
-
Global Development of Pharma Enterprises and Emerging Market Cooperation
-
Legal Safeguard and Value Empowerment for Globalization of Chinese Pharma Enterprises
-
JunHe LLP Session:New Models of Cross-Border Pharmaceutical Cooperation Session
-
Protheragen Session: Global Biomedical Cross-Border Transactions
-
Nanobody Drug R&D Session
Stay tuned
Opening Remarks
Changchun Zha：Chairman, Biointron
Progress of Nanobody‑based Therapeutics & Applications in ADCs
Haikun Shi: Founder & Chairman, Kunyu Biotech
Development of Nanobody Therapeutics for Diabetic Nephropathy
Jiajun Fan: Director & Principal Investigator, Institute of Biotech Pharmaceuticals, Quzhou Fuda Biomedical Innovation Institute; Shanghai Rising Star Young Scientist
Dual-Epitope Nanobodies for Acute Disease Therapy Strategies
Mingyue Huang: Founder, Chairman & CEO, BiyoPharma
Applications of Diverse Screening Platforms in Nanobody Discovery
Lei Shi: Senior Vice President, Biointron
Roundtable: Challenges and Future of Next‑Generation Antibody Drugs
Moderator: Haikun Shi: Founder & Chairman, Kunyu Biotech
Shuqing Chen: Professor & Doctoral Supervisor, College of Pharmaceutical Sciences, Zhejiang University; Founder & Chairman, Neoantigen
Jun Wang: General Manager,Jushi Biotech,CSPC Pharmaceutical Group
Tao Xu: Founder & CEO, SmartNuclide
Jing Huang: COO & CBO, Novamab
Mingyue Huang: Founder, Chairman & CEO, BiyoPharma
CNS Novel Drug R&D Session
Stay tuned
Development of New Molecular Entity Drugs for Antipsychotic Indications
Tian Jingwei: Executive Vice President of R&D, Luye Pharma Group; Dean, School of Pharmacy, Yantai University
Medical Use and Market Prospects of Modified Psychedelics in Light of the FDA's New Guidance and Trump's Executive Order
Shen Huajiong: Founder & CEO, NeuShen Therapeutics
“PRODEGRE ATLAS – A Protein Degradation Innovation Platform to Enable Breakthrough Therapies for CNS Disorders”
Tan Shen: Co-Founder & CEO, Pridarray Biotech
Universal iPSC-Derived Cell Therapy for Brain Injury-Related Disorders
Fan Jing: Founder & CEO, Hopstem Biotechnology
Development of a Novel Small Molecule Drug for Stroke
Chen Rong: Deputy General Manager, Ningen Pharma
Development and Global Pathway of QP001 Injection
Yu Sen: VP, Qingpu Biopharma
Preliminary Validation of iPSC-Based Therapies for CNS Diseases Derived from the SISBAR Core Technology Platform
Wu Lanlin: CEO, Yuesai Biotechnology
Expanding the Extrabepatic Application of Small Nucleic Acid Drugs – R&D Progress in CNS Diseases
Gao Shan: Senior Vice President & Chief Scientist, Ribo Life Science
Research Progress of Cyclopolysaccharide Analog AMCDx Platform in CNS Diseases
Qi Youmao: Chairman, Aomu Pharma; Head of Academician Workstation; Chief Scientist
The Path to Clinical Translation of Innovative Biopharmaceuticals – Opportunities, Challenges, and Collaboration
Si Tianmei: Vice President, Peking University Sixth Hospital; Deputy Director, Institute of Mental Health
Frontier Technology in Innovative Drug Development
Isaac Cheng: VP of Research, Suntec Medical
Discovery and Development of a Novel Dual-Target, Non-Opioid Potent Analgesic
Sheng Xijun: Director, Innovation Research Center, Yichang Humanwell
Panel Discussion – The Future of CNS Drug R&D
Hei Yongjiang: Founder, Huisibo Biotech
Fang Qun: Chief Scientific Officer, Yisi Biotech; Head, Brain Science Innovation R&D Center
Li Qun: General Manager, Saipute
Wang Bingjie: CBO, Sunshine Angene Biotech
Advanced Stem Cell Culture Process Symposium
Stay tuned
Moderator：Shang Xiao，Founder & Chairman, Youyi Bio
Culture of MSC: from 2D to 3D, and beyond
Lianming Liao：CSO, Tuohong Bio
High-Efficiency Exosome Production Factory Driven by All-Factor Integrated Medium
Ali Mohsin：VP of R&D, Youyi Bio
Roundtable 1: Implementation of Documents No. 818 and No. 828 – Risks and Challenges in Cell Therapy Supply Chain under Dual Regulatory Frameworks
Yutian Shen: CEO, Saijun Bio
Zhiying He: Distinguished Researcher & Executive Director，Institute for Regenerative Medicine，Shanghai East Hospital of Tongji University
Yonghong Yin: Deputy GM, Sailiwei Bio
Yijie Yang: Co-founder & CEO, Shenzhen Huixin Bio-Medical Technology Co., Ltd.
Yueming Wang: CEO, Yuanxin Excellence Bio; International Advisor, Beijing Daxing International Airport Economic Zone
Ting Zhang: CEO, Gemrisen
Roundtable 2: Compliance and Prospects of MSC Cell Therapy
Wei Wu（Moderator): General Manager, Suzhou Youyi Bio
Chencai Liu: Deputy GM, Qichuang Research Institute
Lin Shi: Chief Medical Officer, Jinfeng Laboratory; former VP of Yuanda Medical; Vice Chairperson, CBIITA Consortium; Professor
Guanghua Yang: Chief Scientist, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine; Chairman, Heji (Shanghai) Medical Technology Co., Ltd.
Zhang Wenjun: Deputy Director, Institute of Hematology, Tongji University; Deputy Director, Oncology Center, Tongji Hospital; Deputy Director, Institute of Hematology, Tongji University School of Medicine
PAN SWEE TING: Managing Director & Head of China, JIF Capital
The Booming Radiopharmaceuticals Session
Stay tuned
Opening Remarks
Yumin Zhang: Founder, Anchoray Inc.; Radiopharmaceutical Advisor, Tonacea; Honorary Chairman, Chinese American Society of Nuclear Medicine and Molecular Imaging (CASNMMI)
Innovative Design of Radiopharmaceuticals
Zhen Cheng: Director, Molecular Imaging Center, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences; Fellow of American Institute for Medical and Biological Engineering, Society for Radiopharmaceutical Sciences, International Society for Optics and Photonics, Royal Society of Chemistry, and International Association of Advanced Materials
Case Analysis of Preclinical Evaluation for Radiopharmaceuticals
Conglin Zuo: Founder, Hexin Pharmaceutical ; Vice Chairman, JOINN Laboratories; Member of the Drug Toxicology Committee, Chinese Pharmacological Society；Member, Drug Safety Evaluation Research Committee, Chinese Pharmaceutical Association
Clinical Development Strategies for Radiotherapeutic Drugs in Oncology
Yan Gong: General Manager, Honghong Pharma
Roundtable 1: Promising Investment Directions for Radiopharmaceuticals Beyond 2026
Tao Xu(Moderator): Founder & CEO, SmartNuclide; Secretary-General, Tonacea Radiopharmaceutical Club
Li Li: Partner, Stars Capital
Chunguang Liu: Managing Partner, Tailong VC
Feng Yu: Founder & CEO, ELI Radiopharma
Roundtable 2: The Synergy Between Isotopes and Radiopharmaceuticals
Jianguo Li(Moderator): Party Secretary & Deputy Director, China Institute for Radiation Protection (CIRP)
Hong Liu: Chairman, Baiyunshan Rare Nuclide Health
Jim Cai: Chairman & CEO, New Radiomedicine Technology
Bo Shan: CEO, BoomRay Pharmaceuticals
Xiangsheng Ye: CSO, AlphaGen Therapeutics
Roundtable 3:What Big Pharma Seeks in Radiopharmaceuticals？
Wuzhou Wan: President, Central Research Institute, Yunnan Baiyao Group
Fang Li: Director, BD Search & Evaluation, Novartis China
Duan Wang: Director, Frontier Innovation Collaboration, Bayer Pharmaceuticals China Innovation Hub
More guests to be confirmed...
Follow or Contact Us
Follow the TONACEA Official WeChat Account and scan the QR code to register. Stay updated with the latest conference news.
Public Account QR Code
Registration QR Code
Conference Service Hotline
© 2026 TONACEA (Shanghai) Technology Development Co., Ltd. All rights reserved. All rights reserved.
